IBR-822

Phase I dose escalation phase: evaluate the safety and tolerability of IBR822, determine the maximum tolerated dose (MTD) and/or phase II recommended dose (RP2D) of IBR822. Secondary purpose: researchers preliminarily evaluate the anti-tumor efficacy of different doses of IBR822 in patients with advanced solid tumors according to the solid tumor clinical efficacy evaluation criteria and immune-related solid tumor clinical efficacy evaluation criteria; describe the pharmacokinetic (PK) characteristics of IBR822 cells; evaluate the immunogenicity of IBR822 cell injection. Retrospective analysis of the correlation between tumor antigen Trop2 expression and efficacy. Phase IIa cohort expansion phase: primary purpose: further evaluate the safety and tolerability of IBR822 in the treatment of patients with Trop2-positive advanced solid tumors under the determined RP2D, and determine the later recommended dose of IBR822; in the study population with known Trop2 expression, the anti-tumor efficacy of IBR822 evaluated by researchers according to RECIST v1.1 and iRECIST standards. Secondary purpose: analyze the correlation between tumor antigen Trop2 expression and efficacy. To evaluate the pharmacokinetic (PK) characteristics of IBR822 in patients with Trop2-positive advanced solid tumors and to evaluate the immunogenicity of IBR822 in patients with Trop2-positive advanced solid tumors.